Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Eli Lilly Says Antibody Combo Effective Against COVID, Asks for EUA

by Global Biodefense Staff
October 7, 2020
Eli Lilly Says Antibody Combo Effective Against COVID, Asks for EUA

Eli Lilly and Company today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

Data from a new interim analysis of the BLAZE-1 clinical trial showed that combination therapy with two of Lilly’s SARS-CoV-2 neutralizing antibodies reduced viral load, symptoms and COVID-related hospitalization and ER visits.

The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555 and LY-CoV016, which bind complementary regions of the SARS-CoV-2 spike protein, for the treatment of symptomatic COVID-19 in the outpatient setting. The combination cohort enrolled recently diagnosed patients with mild-to-moderate COVID-19, who were assigned to 2800 mg of each antibody (n=112) or placebo (n=156).

The combination therapy significantly reduced viral load at day 11, meeting the primary endpoint of the study.

Lilly has now submitted an initial request for Emergency Use Authorization (EUA) for LY-CoV555 monotherapy in higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19.

“The monoclonal neutralising antibody drugs are very promising with slightly different versions being developed by several pharmaceutical companies.  This announcement from Eli Lilly follows broadly similar results reported by Regeneron last week,” notes Prof Martin Landray, Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford. “Both studies show that monoclonal antibodies targeted at the coronavirus spike protein can reduce the viral load and improve symptoms.  Although Eli Lilly report that fewer patients receiving the treatment were admitted to hospital or attended the emergency room than in the placebo group, this should be interpreted with caution in such a small study.”

Lilly expects to submit a subsequent request for EUA for combination therapy in November, pending clinical trial enrollment, once additional safety data accumulate and sufficient supply is manufactured. Lilly anticipates having data to support a biologics license application (BLA) submission for combination therapy as early as Q2 2021.

“There is a way to go before we know whether this class of drugs is effective in reducing the worst manifestations of COVID,” said Professor Landray.  “We need to know if they improve outcomes for patients – avoid hospital admission, shorten hospital stay, reduce need for mechanical ventilation, and improve survival.  Furthermore, it is important to establish how well they work in different types of patients (the elderly, particular ethnic groups, those with other disease) and at different stages of the disease (early vs. late, mild vs. severe, requiring oxygen or mechanical ventilation). Randomised clinical trials to answer these questions are now a priority.  It is encouraging to see that both Eli Lilly and Regeneron have active plans for much larger trials in a range of different settings including residential care homes, outpatients, and hospital inpatients.”

Lilly says it is working to publish the monotherapy and combination therapy data in peer-reviewed journals as soon as possible.

Tags: COVID CountermeasuresCOVID-19Editor PickEmergency Use AuthorizationSARS-CoV-2Therapeutic Antibodies

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC